Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether access to Evusheld will form part of their commitment to providing early access to (1) life-saving, and (2) cutting-edge, medicines through the Innovative Medicines Fund.

The Innovative Medicines Fund will support patient access to the most promising new medicines while further evidence is collected on use to address clinical uncertainty. The National Institute for Health and Care Excellence (NICE) considers any non-cancer medicine referred to its technology appraisal or highly specialised technologies programmes for managed access via the Innovative Medicines Fund.

However, as Evusheld for the prophylaxis of COVID-19 has not been referred to NICE for evaluation, it is not currently being considered for funding through the Innovative Medicines Fund. We have asked clinicians to advise on the most appropriate option for the National Health Service in line with the available data, the public health situation and other treatments available.